Intravenous Enhancin[Co-amoxiclav] Versus Postoperative Enhancin in Prevention of Postadenotonsillectomy Morbidity.
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Null hypothesis; The efficacy of Enhancin]Co-Amoxiclav given as a single intravenous dose at
induction is not better than a five days oral course of the same given postoperatively in
reducing postoperative morbidity after adenotonsillectomy.